retatrutide availability clinical trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a This weight-loss drug hasn't been
Description
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity
It may not lead to immediate harm in all cases, but it is not considered best practice
If you are self-administering your medication at home, we schedule follow-up appointments every 6 weeks either by phone or in personto monitor your progress, address any concerns, and ensure your treatment is safe and effective
Drugs 6 (4), 209217
As a result, patients often experience reduced cravings, improved metabolic health, and consistent weight loss over time
Of the 992 participants on an SGLT2i, 65% (647 individuals) were still on therapy for at least 3 years
